Recombinant Human PD-1 Protein
Referencia P613-50
embalaje : 50ug
Marca : Leinco Technologies
Contact local distributor :
Teléfono : +1 850 650 7790
Recombinant Human PD1 Protein
Recombinant Human PD1 Protein
Product No.: P613
Target PD1 Product Type Recombinant Protein Alternate Names PD1, PDCD1, CD279 Applications ELISA , FA , WB |
Antibody DetailsProduct DetailsExpression Host HEK293 Cells Reconstitution Reconstitute at 1mg/ml using filtered deionized water. Gently mix by vortexing and/or inversion for 5 minutes or until fully dissolved. Centrifuge if necessary. State of Matter Lyophilized Storage and Handling 1 month, 2 to 8 °C under sterile conditions after opening and reconstituting. 1 year from date of receipt, 20 to 80 °C as supplied. 3 months from date of receipt, 20 to 80 °C sterile conditions after opening and reconstituting. Regulatory Status Research Use Only Country of Origin USA Shipping Ambient Amino Acid Sequence LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQT Applications and Recommended Usage? Quality Tested by Leinco WB, ELISA, FA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionBackground Human Programmed Death 1 (PD1) is a receptor located on the surface of various cell types including Tcells, Bcells, and some myeloid cells 1 . Its primary function involves regulating the immune system by inhibiting Tcell activation. This process is crucial for promoting selftolerance and minimizing autoimmune reactions. PD1 interacts with its ligands, PDL1 and PDL2, to effectively suppress Tcell activation and the production of cytokines. This mechanism is frequently exploited by cancers as a means to evade the immune response 2, 3. The interaction between PD1 and PDL1 has become a focus in cancer immunotherapy 4. Promising advancements have been made by blocking antibodies targeting PD1, such as nivolumab and pembrolizumab. These antibodies have shown benefits in treating various cancer types such as melanoma, nonsmall cell lung cancer, and renal cell carcinoma. They achieve this by enhancing T cell function within the tumor microenvironment 5 7. These treatments demonstrate how understanding the role of PD1, in Tcell activity can lead to the development of immunotherapeutic strategies. Ligand/Receptor hPDL1 NCBI Gene Bank ID Research Area Cancer . Cell Biology . ImmunoOncology . Immunology . Signal Transduction References & Citations1. Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. J Clin Pathol. 2018;71(3):189194. 2. Jiang Y, Chen M, Nie H, Yuan Y. Human Vaccines & Immunotherapeutics. 2019;15(5):11111122. 3. Blank C, Gajewski TF, Mackensen A. Cancer Immunol Immunother. 2005;54(4):307314. 4. Dong Y, Sun Q, Zhang X. Oncotarget. 2017;8(2):21712186. 5. Homet Moreno B, Parisi G, Robert L, Ribas A. Semin Oncol. 2015;42(3):466473. 6. Ohaegbulam KC, Assal A, LazarMolnar E, Yao Y, Zang X. Trends Mol Med. 2015;21(1):2433. 7. McDermott J, Jimeno A. Drugs Today (Barc). 2015;51(1):720. |